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Blood pressure changes after renal denervation at 10 European
expert centers
A Persu1,2, Y Jin3, M Azizi4, M Baelen1,2, S Vo¨lz5, A Elvan6, F Severino1, J Rosa7, A Adiyaman6, FE Fadl Elmula8, A Taylor9,
A Peche`re-Bertschi10, G Wuerzner11, F Jokhaji12, T Kahan12, J Renkin1, M Monge4, P Widimsky´7, L Jacobs3, M Burnier11,
PB Mark9, SE Kjeldsen8, B Andersson5, M Sapoval4 and JA Staessen3,13 on behalf of the European Network COordinating research
on Renal Denervation (ENCOReD)14
We did a subject-level meta-analysis of the changes (D) in blood pressure (BP) observed 3 and 6 months after renal denervation
(RDN) at 10 European centers. Recruited patients (n¼ 109; 46.8% women; mean age 58.2 years) had essential hypertension
conﬁrmed by ambulatory BP. From baseline to 6 months, treatment score declined slightly from 4.7 to 4.4 drugs per day. Systolic/
diastolic BP fell by 17.6/7.1mmHg for ofﬁce BP, and by 5.9/3.5, 6.2/3.4, and 4.4/2.5mmHg for 24-h, daytime and nighttime BP
(Pp0.03 for all). In 47 patients with 3- and 6-month ambulatory measurements, systolic BP did not change between these two time
points (PX0.08). Normalization was a systolic BP ofo140mmHg on ofﬁce measurement oro130mmHg on 24-h monitoring and
improvement was a fall of X10mmHg, irrespective of measurement technique. For ofﬁce BP, at 6 months, normalization,
improvement or no decrease occurred in 22.9, 59.6 and 22.9% of patients, respectively; for 24-h BP, these proportions were 14.7,
31.2 and 34.9%, respectively. Higher baseline BP predicted greater BP fall at follow-up; higher baseline serum creatinine was
associated with lower probability of improvement of 24-h BP (odds ratio for 20-mmol l 1 increase, 0.60; P¼ 0.05) and higher
probability of experiencing no BP decrease (OR, 1.66; P¼ 0.01). In conclusion, BP responses to RDN include regression-to-the-mean
and remain to be consolidated in randomized trials based on ambulatory BP monitoring. For now, RDN should remain the last
resort in patients in whom all other ways to control BP failed, and it must be cautiously used in patients with renal impairment.
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INTRODUCTION
Depending on populations studied and applied methods and
deﬁnitions, the prevalence of treatment-resistant hypertension
varies from 10–15%.1 The SYMPLICITY studies2–4 demonstrated that
in this indication catheter-based endovascular sympathetic renal
denervation (RDN) by means of low-frequency energy is feasible.
It entails a 25–30mmHg decrease in ofﬁce systolic blood pressure
(BP), 84% of patients achieving a decrease in ofﬁce systolic BP of
10mm Hg or more with a rate of procedural adverse events lower
than 5%.3 However, as reviewed elsewhere,5,6 the SYMPLICITY
reports and subsequent studies7 did not yet generate conclusive
evidence. The post-procedural changes in the ambulatory BP,
regrettably reported in few studies, did not always reach statistical
signiﬁcance.7 Finally, the nonrandomized open design of most RDN
studies and publication bias limit the inferences that can be made
from published data.7,8
To address these concerns, we performed a subject-level
meta-analysis of the responses of the ofﬁce and ambulatory BP
6 months after RDN at 10 expert centers involved in the
European Network COordinating research on Renal Denervation
(ENCOReD). In addition, we compared our current ﬁndings with
those observed in the SYMPLICITY HTN-2 trial3 and in elderly
patients with isolated systolic hypertension,9 another difﬁcult-to-
control hypertension subtype.1,10,11
SUBJECTS AND METHODS
Patients undergoing RDN
We carried out systematic reviews of the literature published elsewhere,6,7
and identiﬁed ENCOReD centers engaging in RDN. Patients being followed up
in the framework of still ongoing investigator-initiated or industry-sponsored
trials or observational studies awaiting independent publication could not be
included. Following the 4th ENCOReD network meeting, held in Leuven on 26
April 2013, 10 centers with patients available according to the foregoing
criterion volunteered to contribute data to this patient-level meta-analysis.
Participating centers provided information on 166 consecutively enrolled
patients who underwent RDN because of resistant hypertension. Of those, we
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excluded 57 because they did not have their ambulatory BP measured either
at baseline or at 6 months of follow-up. The number of patients eligible for
inclusion in the current analysis therefore totaled 109, of whom 47 had an
intermediary assessment of their BP at 3 months.
The eligibility criteria for RDN at the participating centers complied with
European consensus12 and included: (i) optimized and stable treatment for at
least 6 weeks with three or more antihypertensive drug classes at the
maximal-tolerated dose, preferably including a diuretic (all 10 centers), or
intolerance to all antihypertensive drugs (two patients in one center); (ii) a
systolic BP on ofﬁce measurement of at least 140mmHg (ﬁve centers) or
160mmHg (150mmHg in diabetic patients; two centers), a daytime or
24-h systolic BP of at least 135 or 130mmHg, respectively (eight centers); (iii)
an estimated glomerular ﬁltration rate (eGFR)13 of 30mlmin 1 per 1.73m2 or
higher; (iv) systematic exclusion of secondary hypertension; (v) suitable
anatomy of the renal arteries2,3 (vi) and approval by each center’s Institutional
Review Board and signed informed consent. As in SYMPLICITY HTN-23 and in
line with current European12 and French14 guidelines nonsigniﬁcant (o50%)
lesions of the renal arteries were not an exclusion criterion. The RDN systems
used included Symplicity Catheter System (Ardian, Mountain View, CA, USA)
in 98 (89.9%) patients and other catheters in 11 (10.1%).
Reference groups
The ﬁrst reference group consisted of patients with resistant hypertension,
who were randomized in the SYMPLICITY HTN-2 trial and completed the
6-month follow-up either on usual therapy (n¼ 51) or after RDN (n¼ 49).3
The second reference group included 152 patients, who were randomized
in the Systolic Hypertension in Europe trial (Syst-Eur) and who had their
ambulatory BP measured twice during the 3-month run-in period,15 while
on single-blind placebo treatment and 6 months after randomization on
treatment with either placebo (n¼ 73) or active drugs (n¼ 79). A more
detailed description of the reference groups is available in the study by
Esler et al.3 for SYMPLICITY HTN-2 and in the study by Staessen et al.9 and
in the online-only Expanded Methods for Syst-Eur.
BP measurement
In the RDN studies and in the Syst-Eur trial contemporary guidelines for the
measurement of BP were applied.16–18 In the current RDN studies, ofﬁce BP
was measured either by auscultation of the Korotkoff sounds (one center)
or by validated oscillometric devices (nine centers). The number of ofﬁce
readings averaged per visit ranged from two to ﬁve. All participating
centers used validated portable monitors to measure the ambulatory BP
according to the guidelines of the European Society of Hypertension.18
Daytime and nighttime were deﬁned using diaries and long ﬁxed-time
clock intervals.19 Across centers, the intervals between daytime and
nighttime readings ranged from 15 to 30min and from 20 to 60min,
respectively. The white-coat effect was ofﬁce minus 24-h or daytime BP.
Statistical methods
We used SAS, version 9.3, for database management and statistical analysis.
We applied t-tests to compare unadjusted means and to determine the
signiﬁcance of unadjusted within-group BP changes (follow-up measurement
subtracted from baseline) and the w2-statistic to compare proportions. To
compute signiﬁcance of BP changes, while adjusting for baseline and
accounting for center or study as a random effect, we applied a generalization
of the standard linear model, as implemented in the PROC MIXED procedure
of SAS package. In multivariable-adjusted analyses, we considered sex, age,
body mass index, serum creatinine and a history of diabetes mellitus or
cardiovascular disease as potential predictors of the BP responses. We also
applied multivariable-adjusted logistic regression to identify predictors of BP
status at 6 months of follow-up. As in the SYMPLICITY studies,2–4 reaching
systolic BP control was deﬁned by achieving levels below 140mmHg on
ofﬁce or below 130mmHg on 24-h ambulatory measurement, respectively.
Improvement was deﬁned as a decrease in the ofﬁce or 24-h systolic BP by at
least 10mmHg.2,3 No decrease in BP was deﬁned as a systolic BP at 6 months
equal to or higher than the baseline value. Signiﬁcance was deﬁned as a P-
value of 0.05 or less.
RESULTS
Baseline characteristics
Table 1 lists the baseline characteristics of the patients who
underwent RDN by level of ofﬁce systolic BP before RDN.
Supplementary Table S1, available in the online-only Data
Supplement, provides the same baseline characteristics by center.
Of the 109 RDN patients, 23 (21.1%) had isolated systolic
hypertension, 12 (11.0%) had taken part in the SYMPLICITY HTN-
2 trial3 and 4 (3.7%) had an ofﬁce systolic BP ofo140mmHg but a
24-h systolic BP higher than 137mmHg. Supplementary Table S2
lists systolic BP at baseline by center.
Unadjusted analyses of the responses to RDN
In 97 (88.9%) patients with information available in our data set, the
number of drug classes taken decreased from 4.7±1.5 (s.d.) at
baseline to 4.4±1.7 at 6 months (P¼ 0.001). All BP reductions at
6 months were signiﬁcant (Pp0.030; Table 2). The systolic/diastolic
reductions averaged 17.6/7.1mmHg for ofﬁce BP, and 5.9/3.5mmHg,
6.2/3.4mmHg and 4.4/2.5mmHg for the 24-h, daytime and night-
time BP values, respectively. From baseline to 6 months of follow-up,
the systolic/diastolic white-coat effect, as assessed by 24-h
ambulatory or daytime BP monitoring, decreased (Po0.001) by
12.0/3.7mmHg and by 11.8/3.7mmHg, respectively. Figure 1 shows
that in 47 patients with measurements available at 3 and 6 month,
ofﬁce and 24-h systolic BP levels were similar at these two time points
(PX0.080). Supplementary Table S2 provides information on the
post-procedural changes in BP by center. The individual responses to
RDN were highly variable (Figure 2), with increases in ofﬁce and 24-h
systolic BPs in 25 (22.9%) and 38 (34.9%) patients (Table 3). Ofﬁce or
24-h systolic BP was at goal under antihypertensive treatment in 25
(22.9%) and 16 (14.7%) of 109 patients, respectively; in RDN patients
with an ofﬁce systolic BP of at least 160mmHg, these numbers were
12 (16.2%) and 8 (10.8%).
The procedural complications encompassed hematomata at the
puncture site (n¼ 8), progression of a nonsigniﬁcant (o30%) renal
artery stenosis (n¼ 3), transient decline in renal function (n¼ 1)
and orthostatic hypotension in medication-intolerant and there-
fore initially untreated patients (n¼ 2).
Adjusted analyses of the responses to RDN
In analyses adjusted for the baseline BP as ﬁxed effect and center
as random effect, the systolic/diastolic responses (Pp0.014) were
Table 1. Characteristics of 109 patients by level of office systolic
pressure
Baseline
characteristic
Office systolic blood pressure
o160mm Hg 160–179mm Hg X180mm Hg
Number of patients 35 33 41
Number (%) with characteristic
Non-white
ethnicity
2 (5.7) 0 (0) 2 (4.9)
Women 10 (28.6) 11 (33.3) 30 (73.2)z
Diabetes mellitus 9 (25.7) 11 (33.3) 8 (19.5)
Previous cardiovascular disease
Coronary heart
disease
7 (20.0) 10 (30.3) 8 (19.5)
Stroke 4 (11.4) 3 (9.1) 2 (4.9)
Mean (s.d.) characteristic
Age, years 57.6±10.8 60.3±11.1 57.1±11.8
Body mass index,
kgm 2
28.1±4.2 30.6±4.5* 29.7±5.2
Serum creatinine,
mmol l 1
92.8±30.8 92.6±23.2 72.0±19.7z
eGFR, mlmin 1
per 1.73m 2
76.5±21.9 77.5±22.9 90.9±27.1*
eGFR indicates the glomerular filtration rate estimated from the serum
creatinine concentration.13 Significance of the difference with the left
adjacent column: *Pp0.05; zPp0.001.
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14.2/6.5mmHg for ofﬁce BP, and 5.2/3.1mmHg, 5.6/3.3mmHg
and 4.9/2.3mmHg for the 24-h, daytime and nighttime BPs,
respectively (Table 2). Adjusted estimates for the decreases in the
systolic/diastolic white-coat effect derived from 24-h or daytime
recordings were 7.7/2.6mmHg and 8.4/2.6mmHg, respectively
(Pp0.011). Multivariable-adjusted analyses of ofﬁce and 24-h
systolic BP level achieved 6 months after RDN revealed that higher
baseline values were associated with greater fall in BP (Po0.001;
Supplementary Table S3). Previous cardiovascular disease pre-
dicted a 9.8mmHg greater decline in ofﬁce systolic BP (P¼ 0.048)
and a 20-mmol l 1 higher serum creatinine concentration at
baseline predicted a 2.8-mmHg lesser decrease in 24-h systolic BP
(P¼ 0.048).
In multivariable-adjusted categorical analyses of the systolic BP
responses (Table 4), baseline levels of BP and serum creatinine
were the predominant predictors (Table 4). Higher baseline BP was
associated with lower probability of reaching BP control (odds
ratio (OR) for ofﬁce and 24-h systolic BP, 0.78 and 0.49; Pp0.039),
higher probability of experiencing a decrease in systolic BP by
10mmHg or more (OR, 1.36 and 1.31; Pp0.059) and lower
probability of experiencing no decrease in ofﬁce systolic BP (OR,
0.71; Pp0.013). Higher serum creatinine concentration was
associated with lower probability of systolic BP control on 24-
ambulatory monitoring (OR, 0.53; P¼ 0.082) or improvement of
systolic BP on ofﬁce or 24-h ambulatory measurement (OR, 0.61
and 0.60; Pp0.050) and higher probability of experiencing no
decrease in systolic BP (OR, 1.80 and 1.66; Pp0.016).
Comparison with SYMPLICITY HTN-2 Patients
After exclusion of our current patients with a baseline systolic BP
on ofﬁce measurement ofo160mmHg to match the SYMPLICITY
recruitment criteria, the proportion of our current patients
experiencing no decrease or an improvement was of similar
magnitude as in the SYMPLICITY HTN-2 report,3 whereas control
was reached in fewer of our current patients (Figure 3).
Comparison with Syst-Eur patients
At baseline, systolic BP on ofﬁce and 24-h, daytime and night-
time measurement and the serum creatinine concentration
were similar (PX0.12) among RDN and Syst-Eur patients
(Supplementary Table S4). Compared with our current RDN
patients, at 6 months, ofﬁce systolic BP ( 17.6 vs  7.7mmHg)
and the white-coat effect derived either from 24-h ( 12.0 vs
Table 2. Baseline values and 6-month Changes in blood pressure
in 109 patients
Variable Systolic pressure Diastolic pressure
Office, mmHg
BL 174.5±25.7 98.0±18.6
Du  17.6 ( 22.0 to  13.1)z  7.1 ( 9.8 to  4.5)z
Da  14.2 ( 17.7 to  10.6)z  6.5 ( 8.8 to  4.2)z
24-h, mmHg
BL 156.7±17.4 91.5±14.2
Du  5.9 ( 9.0 to  2.8)z  3.5 ( 5.5 to  1.5)z
Da  5.2 ( 7.9 to  2.6)z  3.1 ( 4.7 to  1.4)z
Daytime, mmHg
BL 160.8±18.0 94.9±15.3
Du  6.2 ( 9.5 to  2.9)w  3.4 ( 5.5 to  1.4)z
Da  5.6 ( 8.3 to  2.8)z  3.3 ( 5.1 to  1.5)z
Nighttime, mmHg
BL 147.0±20.8 83.5±15.1
Du  4.4 ( 7.9 to  1.0)*  2.5 ( 4.8 to  0.2)*
Da  4.9 ( 7.7 to  2.1)z  2.3 ( 4.1 to  0.5)*
Office minus 24-h, mmHg
BL 18.2±22.5 6.7±13.4
Du  12.0 ( 16.4 to  7.7)z  3.7 ( 6.2 to  1.3)w
Da  7.7 ( 10.7 to  4.6)z  2.6 ( 4.6 to  0.7)w
Office minus daytime, mmHg
BL 14.0±22.6 3.3±14.1
Du  11.8 ( 16.2 to  7.4)z  3.7 ( 6.2 to  1.3)w
Da  8.4 ( 11.7 to  5.1)z  2.6 ( 4.6 to  0.6)*
BL, Du and Da respectively indicate baseline value, unadjusted change
(follow-up minus baseline), and change estimates derived from mixed
models, while adjusting for baseline as fixed effect and center as random
effect. Baseline values are mean±s.d. Changes are crude or adjusted
means with 95% confidence interval. Office minus 24-h or daytime blood
pressure is a measure for the white-coat effect. Significance of the changes:
*Pp0.05; wPp0.01; zPp0.001.
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Figure 1. The office and 24-h ambulatory BP values at baseline and
at 3 and 6 months after RDN in 47 patients. SBP and DBP indicate
systolic and diastolic BP, respectively. P-values denote the signifi-
cance compared with baseline in unadjusted analyses.
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Figure 2. Individual responses of systolic (a, c) and diastolic (b, d) BP
on office (a, b) and 24-h ambulatory (c, d) measurement in 109
patients undergoing RDN.
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 5.7mmHg) or daytime (–11.8 vs –5.7mmHg) BP monitoring
decreased less (Pp0.042) in 73 Syst-Eur patients randomized to
placebo, whereas the changes in the ambulatory BP levels were
similar (PX0.13). Among 79 Syst-Eur patients randomized to
active treatment, the decreases in the 24-h and nighttime systolic
BP were larger than in RDN patients (Pp0.013), whereas changes
in daytime systolic BP and in the white-coat effect were similar
(PX0.22). The aforementioned ﬁndings were consistent
(Supplementary Table S5) in mixed models adjusted for baseline,
sex, age, body mass index, diabetes mellitus and a history of
cardiovascular disease (ﬁxed effects) and study (RDN vs Syst-Eur
modeled as random effect).
DISCUSSION
This report is the ﬁrst subject-level meta-analysis of the 6-month
responses of both ofﬁce and ambulatory BP to RDN in carefully
selected patients in whom secondary hypertension was excluded
and who had resistant hypertension conﬁrmed by ambulatory
monitoring. The key ﬁndings were that the BP responses to RDN
were: (i) highly variable in individual patients; (ii) on average
considerably smaller on ambulatory than ofﬁce measurement (iii)
and smaller than reported in previous studies.2–4 The systolic BP
changes averaged  17.6 on ofﬁce measurement and
 5.9mmHg on 24-h ambulatory monitoring, but the individual
responses ranged from  91 to þ 41mmHg and from  63 to
þ 43mmHg, respectively. The decrease in BP was already
achieved at 3 months with no further reduction at 6 months.
Ofﬁce or 24-h systolic BP was at goal under antihypertensive
treatment in 22.9% and 14.7% of 109 patients, respectively.
After exclusion of patients with a baseline systolic BP on ofﬁce
measurement ofo160mmHg, the proportion of our current RDN
patients experiencing no decrease or an improvement was of
similar magnitude as in the SYMPLICITY HTN-2 report,3 whereas
control was reached in fewer of our patients. In the SYMPLICITY
HTN-2 study,3 the 24-h systolic BP decreased by 11±15mmHg
(P¼ 0.006) in 20 RDN patients and did not change in 25 controls
( 3±19mmHg; P¼ 0.51), resulting in a unreported
nonsigniﬁcant between-group difference of 8mmHg, as
recalculated from the published data (t¼ 1.61; P¼ 0.11).
Remarkably, the SYMPLICITY HTN-2 report also did not include
the baseline ambulatory BP in Table 1.3 Our current study reports
on the largest database of ambulatory BP measurements
following RDN.
Our results revealed smaller reductions in the ofﬁce and
ambulatory BP than those observed in the SYMPLICITY HTN-2
trial3 or in a subsequent meta-analysis,20 even though compared
with these other studies3,20 our patients had similar ofﬁce BP,
treatment score, renal function and baseline characteristics, being
mainly white and obese. Davis et al.20 stated that they did a meta-
analysis of summary statistics extracted from two randomized
controlled trials, one observational study with a control group and
nine observational studies without a control group. In controlled
studies, the reduction in ofﬁce systolic BP at 6 months was -28.9
Table 3. Status of systolic blood pressure at 6 months
Variable Office systolic pressure at baseline (mm Hg)
o160 160–179 X180 Whole
range
Number of
patients
35 33 41 109
Office blood pressure
Normalization 13 (37.1) 8 (24.2) 4 (9.8)* 25 (22.9)
Improved 12 (34.3) 21 (63.6)w 32 (78.0) 65 (59.6)
No decrease 14 (40.0) 7 (21.2) 4 (9.8) 25 (22.9)
24-h blood pressure
Normalization 8 (22.9) 6 (18.2) 2 (4.9)* 16 (14.7)
Improved 13 (37.1) 11 (33.3) 10 (24.4) 34 (31.2)
No decrease 13 (37.1) 13 (39.4) 12 (29.3) 38 (34.9)
Values are number of patients (%). Reaching normal systolic blood pressure
was achieving levels o140 mm Hg or o130 mm Hg on office or 24-h
ambulatory measurement, respectively. Improvement was a decrease in
the office or 24-h systolic pressure by X10mmHg. No decrease was a
systolic pressure at 6 months equal to or higher than the baseline value.
Numbers do not add up, because of overlap between categories of
achieved blood pressure. Significance of the difference with the left
adjacent subgroup: *0.07pPp0.09; wP¼ 0.01.
Table 4. Baseline predictors of the 6-month responses of office and 24-h systolic blood pressures to renal denervation in 109 patients
Blood pressure control Improved blood pressure control No decrease in blood pressure
Office blood pressure, mmHg
Number of patients in category (%) 25 (22.9) 65 (59.6) 25 (22.9)
Baseline (þ 10mmHg) 0.78 (0.61–0.99)w 1.36 (1.10–1.69)z 0.71 (0.54–0.93)z
Being female (0,1) 1.12 (0.30–4.00) 1.00 (0.31–3.28) 1.41 (0.33–5.99)
Age (þ 10 years) 0.81 (0.52–1.27) 0.72 (0.47–1.10) 1.36 (0.85–2.16)
Body mass index (þ 5 kgm 2) 0.62 (0.34–1.14) 1.20 (0.70–2.07) 0.62 (0.31–1.25)
Serum creatinine (þ 20mmol l 1) 1.01 (0.66–1.54) 0.61 (0.39–0.97)w 1.80 (1.11–2.91)w
Having diabetes (0,1) 2.19 (0.64–7.49) 1.38 (0.42–4.53) 0.46 (0.11–1.97)
Cardiovascular disease (0, 1) 1.08 (0.29–3.95) 5.39 (1.41–20.6)w 0.59 (0.14–2.56)
24-h blood pressure, mm Hg
Number of patients in category (%) 16 (14.7) 34 (31.2) 38 (34.9)
Baseline (þ 10mmHg) 0.49 (0.39–0.79)z 1.31 (0.99–1.73)* 0.90 (0.69–1.17)
Being female (0,1) 0.73 (0.15–3.55) 0.52 (0.17–1.64) 1.80 (0.59–5.55)
Age (þ 10 years) 0.78 (0.44–1.40) 1.35 (0.88–2.07) 0.68 (0.45–1.03)*
Body mass index (þ 5 kgm 2) 0.72 (0.36–1.47) 0.66 (0.40–1.09)* 1.19 (0.73–1.94)
Serum creatinine (þ 20mmol l 1) 0.53 (0.26–1.09)* 0.60 (0.36–1.00)w 1.66 (1.11–2.49)z
Having diabetes (0,1) 1.27 (0.28–5.72) 1.43 (0.45–4.56) 1.36 (0.46–4.04)
Cardiovascular disease (0, 1) 3.39 (0.69–16.7) 0.49 (0.14–1.70) 0.60 (0.18–1.96)
Values are independent odds ratios with 95% confidence interval. All estimates were adjusted for the baseline systolic blood pressure and for all other
predictors considered (see Table 3). Reaching control was achieving a systolic pressure o140mmHg or o130mmHg on office or 24-h ambulatory
measurement, respectively. Reaching improved control was a decrease in the office or 24-h systolic pressure by X10mmHg. No decrease was a systolic
pressure at 6 months equal to or higher than the baseline value. Significance of the odds ratios: *Pp0.10; wPp0.05; zPp0.01.
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compared with medically treated patients.20 In uncontrolled
studies, there was a reduction by  25.0mmHg.20 The high
variability of the individual BP responses to RDN might explain
why in some studies ofﬁce BP,21 ambulatory BP22–24 or both25 did
not decrease. Other reasons that might explain at least in part
differences in the estimates of the responses to RDN are: (i) a
stringent selection of patients with truly resistant hypertension
conﬁrmed by ambulatory BP monitoring, in whom secondary
hypertension was excluded by an extensive workup and in whom
treatment had been optimized26 and (ii) the high quality of the
ofﬁce and ambulatory BP measurements at the top European
centers that participated in the current study.
In our current study, the average decrease in the 24-h systolic BP
was only one-third of the reduction in the ofﬁce systolic BP and
much smaller than expected based on the literature.27–30 It
exceeded the placebo effect observed in the Syst-Eur trial by
o4mmHg (see online Supplementary Data). As previously
reported in 244 Syst-Eur patients,27 the ratio of the systolic BP
fall on daytime ambulatory to ofﬁce measurement was 0.59 ( 9.3
vs  16.6mmHg). In the Ambulatory Blood Pressure Monitoring
and Treatment of Hypertension trial,28 this ratio was 0.64 ( 14.3 vs
 22.4mmHg). In the Treatment of Hypertension Based on Home
or Ofﬁce Blood Pressure trial,29 the systolic home-to-ofﬁce ratio was
0.73 ( 13.5 vs  18.6mmHg). In the current RDN patients, this
ratio was only 0.35 ( 6.2 vs  17.6 mm Hg). The discrepancy
between ofﬁce and ambulatory BP in response to RDN and the
small effect of RDN on 24-h systolic BP remain a matter of particular
concern, as the 24-h,31,32 daytime31–33 and nighttime31,32,34 systolic
BP values outperform ofﬁce systolic BP in predicting fatal and
nonfatal and overall and cause-speciﬁc cardiovascular compli-
cations. Consequently, whether RDN would translate into a
reduction of cardiovascular events—the ultimate goal of any
blood-pressure lowering intervention—remains to be proven.
The hypothesis that the sympatholytic effects mediated by RDN
may have more pronounced effects on ofﬁce than on ambulatory
BP by inhibition of the white-coat effect35 remains currently
unproven. A more likely explanation is that a substantial
proportion of the beneﬁts attributed to RDN may reﬂect placebo
effects and/or regression-to-the-mean. In keeping with the
SYMPLICITY data,3,4 higher systolic BP at baseline was associated
with a higher probability of experiencing an improvement in
control and lower probability of experiencing an increase in BP.
This observation identiﬁes regression-to-the-mean as an
important confounder contributing to the BP decrease in RDN
studies. The online Data Supplement highlights that whatever
lowers ofﬁce systolic BP—RDN, placebo or antihypertensive drug
treatment—by deﬁnition, such intervention must decrease the
white-coat effect. Attenuation of the white-coat effect was larger
on antihypertensive drug treatment and RDN compared with
placebo.
The present study must be interpreted within the contest of
potential limitations and strengths. First, the centers contributing
patients applied different recruitment criteria. However, introdu-
cing center as a random effect in the continuous and categorical
analyses of the BP responses to RDN did not materially change our
results. Second, in our study, RDN relied for 90% on the use of the
Ardian–Medtronic system so that our ﬁndings cannot be
extrapolated to other devices with a different design. However,
Davis et al.20 did not ﬁnd any differences between catheter
systems. Third, although we have shown creatinine to be a
signiﬁcant predictor of less effect, the mean eGFR in our patients
was within the normal range. Fourth, our current analysis does
not allow explaining the mechanisms underlying the BP
responses to RDN. As in the SYMPLICITY-HTN2 study,3 none of
the conditions associated with increased sympathetic tone, such
as renal impairment or diabetes mellitus, were associated with a
larger decline in BP in response to RDN. Although our current
study is the largest published so far that uses ambulatory BP
monitoring in RDN patients, lack of statistical power might still
be an issue. Nevertheless, one should consider other possibilities:
(i) sympathetic nervous tone might be less important than
expected in resistant hypertension36 or (ii) the proportion of
ﬁbers ablated using the ﬁrst-generation Ardian–Medtronic cathe-
ter is insufﬁcient, a marker of efﬁcacious nervous ablation still
being unavailable for clinical use in humans. Fifth, the compar-
isons with the SYMPLICITY HTN-2 trial3 and with Syst-Eur9 were
retrospective. Comparisons with SYMPLICITY HTN-2 remained
unadjusted, whereas those with Syst-Eur were multivariable-
adjusted for differences in the baseline patient characteristics
(ﬁxed effects) and for study (random effect). Compared with RDN
patients, Syst-Eur patients were older and leaner, had lower eGFR
and less often suffered from diabetes mellitus or coronary heart
disease (see Data Supplement). However, within the context of
this limitation, the comparison of the effects of RDN in resistant
hypertension with that of antihypertensive drug treatment in
another form of difﬁcult-to-control hypertension—isolated systolic
hypertension—is both relevant and hypothesis-generating.
Finally, not observational studies, but only sufﬁciently powered
randomized clinical trials can address the question whether RDN is
effective and safe and whether its effects differ in patients with
normal as compared with impaired renal function. While the
SYMPLICITY HTN-3 randomized controlled trial (NCT01418261)37 is
expected to be completed within the next few months, it is not
sure that its results can be readily extrapolated to European
countries. Despite the superiority of ambulatory over ofﬁce BP to
predict prognosis,31–34 particularly in the context of resistant
hypertension,32 the primary endpoint of this trial37 is still the
baseline-adjusted between-group difference in ofﬁce systolic BP.
Several smaller European trials ongoing in France (NCT01570777,
NCT01588795) and Norway (NCT01673516) will also report by the
end of this year or next year. These studies and others being
planned include ancillary studies on cardiac and arterial structure
and function that will achieve a high degree of standardization
within the networked ENCOReD centers.
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Figure 3. Proportion of SYMPLICITY-HTN2 patients in the control
(n¼ 51) and RDN (n¼ 49) group and proportion of patients in the
current study that at 6 months had no decrease in the office systolic
BP, a 10-mmHg or greater decrease, or had a systolic BP of
o140mmHg. For the current study, proportions are given for all
patients (n¼ 109) as well as for those who at baseline had an office
systolic BP of 160mmHg or more (n¼ 74). P-values are for the
comparison between the SYMPLICITY HTN-2 RDN group and the
current patients.
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Research priorities for RDN are the unequivocal demonstration
of increased sympathetic nervous activity in patients with resistant
hypertension, proof of effective sympathetic inhibition by RDN, for
instance by stimulating the renal nerves before and after RDN,38
and the identiﬁcation of reliable predictors of BP response to RDN.
From a clinical point of view, only a small minority of treatment-
resistant patients qualiﬁes for RDN.25,39 RDN is an invasive
procedure that is not devoid of risk40–42 and comes at a high
cost. The wide-spread deployment of RDN in routine clinical
practice, in particular on referral to interventionists without
involvement of a multidisciplinary team including a hypertension
specialist,26 does not meet the ethical precept in medicine:
‘primum non nocere’ (primum non nocere (‘ﬁrst, do no harm’) is
one of the principal precepts of medical ethics. Another way to
state it is that, ‘given an existing problem, it may be better not to
do something, or even to do nothing, than to risk causing more
harm than good’. It reminds physicians that they must consider the
possible harm that any intervention might do.). RDN should remain
the last resort in patients in whom all other means to control BP
failed and given our current ﬁndings should be used with restraint
in patients with renal impairment, irrespective of whether the
cause is a diseased kidney or prerenal, such as in heart failure.
What is known about topic
 The SYMPLICITY studies demonstrated that catheter-based endovas-
cular sympathetic renal denervation (RDN) by means of low-frequency
energy is feasible.
 In the SYMPLICITY studies, RDN entailed a 25–30mmHg decrease in
ofﬁce systolic blood pressure (BP), 84% of patients achieving a
decrease in ofﬁce systolic BP of X10mmHg; the post-procedural
changes in the ambulatory BP were reported in few studies and did
not always reach statistical signiﬁcance.
What this study adds
 This report is the ﬁrst published subject-level meta-analysis of the 6-
month responses of ofﬁce and ambulatory BP to RDN.
 The BP response to RDN was highly variable among individual
patients and on average larger on ofﬁce than daytime ambulatory BP
measurement ( 17.6 vs  6.2mmHg).
 In RDN patients, lower initial BP and higher serum creatinine predicted
a smaller BP response.
 The mean BP response to RDN is less than previously reported and
includes placebo effects and regression to the mean.
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